# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Susan B. Anthony (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI014-SYN
- Date: 2026-09-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harold Pemberton, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month heart failure review. **S**

## History of present illness

Miss Anthony returns for her six-month review. She is back to lecturing twice a month and travelling by train, and walks two miles most days. She needed as-needed furosemide twice in three months, both after long train days with restaurant meals, and her weight returned to 56 kg within a day each time. Her cough from the August bronchitis has cleared. She has had no dizziness, falls, or breathlessness except on long stair climbs. **S**

| Element | Detail |
|---|---|
| Interval change | Back to full activity; bronchitis resolved |
| As-needed diuretic | Two doses in three months, after travel days |
| Weight diary | Stable at 56 kg |
| Function | Lecturing twice a month; walking two miles |
| NYHA class | I to II |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; good energy |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or edema |
| Respiratory | Negative | Cough resolved; breathless only on long climbs |
| Neurological | Negative | No dizziness on standing |

4 systems reviewed. **S**

## Current medications

- Furosemide 20 mg oral tablet, one tablet by mouth as needed for a weight gain of more than 1 kg in a day or 2 kg in a week **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/72 mmHg; pulse 70 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 56 kg; BMI 20.6 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 0.9 mg/dL; eGFR: 63 mL/min/1.73 m²; Glucose: 93 mg/dL; KCCQ-12 overall summary: 76. All results are synthetic.

## Change since baseline

- Sodium: 138 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Creatinine: 0.88 mg/dL at baseline, 0.9 mg/dL at this visit **S**
- eGFR: 64 mL/min/1.73 m² at baseline, 63 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 93 mg/dL at this visit **S**
- KCCQ-12 overall summary: 52 at baseline, 76 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Neck | Jugular venous pressure 6 cm |
| Lungs | Clear |
| Heart | Regular rhythm; soft S4 |
| Extremities | No edema |
| Orthostatic blood pressure | No fall on standing |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with preserved ejection fraction, stable** (I50.32). Euvolemic on empagliflozin and spironolactone with rare as-needed furosemide. KCCQ-12 76, up 24 points from baseline. Kidney function and potassium stable (eGFR 63, potassium 4.6). **S**
   - Continue the current regimen and the travel weight plan.
   - Basic metabolic panel and KCCQ-12 every three to six months on the CMID schedule.
2. **Hypertensive heart disease** (I11.0). Blood pressure 126/72 mmHg, below the 130/80 target without orthostatic symptoms. **S**
   - No change.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | Every 3 to 6 months when stable | Completed today | Potassium 4.6, eGFR 63 |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit | Completed today | Euvolemic; orthostatic check normal |
| Survey | NYHA functional class | Every visit | Completed today | Class I to II |
| Survey | KCCQ-12 | Every 3 to 6 months | Completed today | 76, up 24 points from baseline |
| Survey | Depression screen (PHQ-2) | Periodically | Due | Planned at next month's annual wellness visit |
| Laboratory | Iron studies, lipid panel, HbA1c, TSH | Annually | Up to date | Drawn at diagnosis in March; due again next spring |
| Imaging | Echocardiogram | Only with unexplained clinical change | Not indicated | Clinically stable |
| Medication safety | Influenza vaccine | Every season | Due | Planned at next month's annual wellness visit |

## Goal progress

- Reach euvolemia with no ankle edema and a stable dry weight within three months. Outcome by 2026-06-29: Dry weight 56 kg; furosemide changed to as-needed use. **S**
- Improve the KCCQ-12 overall summary score by at least 15 points by the three-month review. Outcome by 2026-06-29: KCCQ-12 rose from 52 to 70. **S**
- Lower blood pressure below 130/80 by the six-month review without orthostatic symptoms. Outcome by 2026-09-28: Blood pressure 126/72; no dizziness on standing. **S**
- Resume a full speaking and travel schedule by the six-month review. Outcome by 2026-09-28: Back to lecturing twice a month with a travel weight plan. **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America
- 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023), American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026), Aether Forge

## Follow-up

- Annual wellness visit next month. Heart failure review with laboratory tests in three to six months. **S**
- Next scheduled visit 2026-10-19: subsequent annual wellness visit. **S**
